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Endogenous myoglobin in breast cancer is
hypoxia-inducible by alternative transcription and
functions to impair mitochondrial activity: a role in tumor
suppression?
Abstract
Recently, immunohistochemical analysis of myoglobin (MB) in human breast cancer
specimens has revealed a surprisingly widespread expression of MB in this non-muscle
context. The positive correlation with hypoxia-inducible factor 2 and carbonic anhydrase IX
suggested that oxygen regulates myoglobin expression in breast carcinomas. Here we report
that MB mRNA and protein levels are robustly induced by prolonged hypoxia in breast cancer
cell lines, in part via HIF-1/-2 dependent transactivation. The hypoxia-induced MB mRNA
originated from a novel, alternative transcription start site 6 kb upstream of the ATG codon.
MB regulation in normal and tumor tissue may thus be fundamentally different. Functionally,
the knockdown of MB in MDA-MB468 breast cancer cells resulted in an unexpected increase of
O2 uptake and elevated activities of mitochondrial enzymes during hypoxia. Silencing of MB
transcription attenuated proliferation rates and motility capacities of hypoxic and,
surprisingly, also fully oxygenated breast cancer cells. Endogenous MB in cancer cells is
apparently involved in controlling oxidative cell energy metabolism, contrary to the mouse
heart, where the targeted disruption of the Mb gene did not effect myocardial energetics and
O2 consumption. This control function of MB seemingly impacts mitochondria and influences
cell proliferation and motility, but it does so in ways not directly related to the facilitated
diffusion or storage of O2. Hypothetically, myoglobins mitochondria-impairing role in
hypoxic cancer cells is part of a novel tumor-suppressive function.
Endogenous myoglobin in breast cancer is hypoxia-inducible by alternative 
transcription and functions to impair mitochondrial activity: a role in tumor 
suppression? 
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Summary 
 
Recently, immunohistochemical analysis of 
myoglobin (MB) in human breast cancer 
specimens has revealed a surprisingly widespread 
expression of MB in this non-muscle context. The 
positive correlation with hypoxia-inducible factor 
2 (HIF-2α) and carbonic anhydrase IX suggested 
that oxygen regulates myoglobin expression in 
breast carcinomas. Here we report that MB mRNA 
and protein levels are robustly induced by 
prolonged hypoxia in breast cancer cell lines, in 
part via HIF-1/-2 dependent transactivation. The 
hypoxia-induced MB mRNA originated from a 
novel, alternative transcription start site 6 kb 
upstream of the ATG codon. MB regulation in 
normal and tumor tissue may thus be 
fundamentally different.  
Functionally, the knockdown of MB in MDA-
MB468 breast cancer cells resulted in an 
unexpected increase of O2 uptake and elevated 
activities of mitochondrial enzymes during 
hypoxia. Silencing of MB transcription attenuated 
proliferation rates and motility capacities of 
hypoxic and, surprisingly, also fully oxygenated 
breast cancer cells. Endogenous MB in cancer cells 
is apparently involved in controlling oxidative cell 
energy metabolism, contrary to the mouse heart, 
where the targeted disruption of the Mb gene did 
not effect myocardial energetics and O2 
consumption (1). This control function of MB 
seemingly impacts mitochondria and influences 
cell proliferation and motility, but it does so in 
ways not directly related to the facilitated diffusion 
or storage of O2. Hypothetically, MB´s 
mitochondria-impairing role in hypoxic cancer 
cells is part of a novel tumor-suppressive function.  
 
Introduction 
 
Mammalian myoglobin (MB) is a cytoplasmic 
heme-containing respiratory protein of cardiac 
myocytes and oxidative type I/IIa skeletal muscle 
fibers. In striated human muscles, MB occurs at 
concentrations of ~200-300 µM. Here, the 
monomeric globin is widely accepted to function 
as a temporary “store” for oxygen, able to buffer 
short phases of exercise-induced increases in O2 
flux during which it supplies the gas to 
mitochondria (2). Another, more controversially 
discussed role is MB`s facilitation of O2 diffusion 
within muscle cells (3,4). Mb knockout (Mb-/-) 
mice exhibited normal development and exercise 
capacity and showed no signs of compromised 
cardiac energetics due to multiple systemic 
compensations (1,5). The fact that these 
compensations (i.e. increases in capillarity, 
coronary flow, coronary reserve and hematocrit) 
acted in concert to reduce the diffusion path length 
for O2 between capillaries and the mitochondria 
strongly argued for the importance of MB with 
regard to the delivery of O2. Follow-up studies 
stressed the additional relevance of functional Mb in 
maintaining nitric oxide (NO) homeostasis in 
muscle through either scavenging (6) or producing 
the NO molecule (7). Beyond transporting/storing 
diatomic gaseous ligands (O2, NO), MB`s 
physiological facets might also include synthesis of 
peroxides (8), scavenging of reactive O2 species (9) 
and binding of fatty acids (10,11). However, the 
oxygenation-support function of MB in myocytes is 
widely accepted and further underscored by the O2-
responsiveness of the MB gene. 
 
Expression of MB was found up-regulated in 
oxidative myofibers of humans in response to 
exposure to high altitudes (12) or intense endurance 
training under reduced O2 pressures (2,12-14). 
Whether or not the hypoxia-inducible factor (HIF)-
1, the chief transducer of falling O2 partial pressure 
(pO2) at the level of DNA, is responsible for this up-
regulated gene activity in humans remains a matter 
of debate. While HIF-1 signaling is known to be 
stimulated in muscle by exercise, with or without 
hypoxia, and in response to muscular stretching 
(13,15,16), conserved HIF-binding hypoxia 
response elements (HREs) are lacking in the 
standard promoter of the MB gene (17). Yet, in 
striated muscles of mice HIF-1 has been implicated 
in the induction of Mb expression during chronic 
hypoxia (18). Contrary to that, when Kanatous and 
co-workers subjected mice to week-long hypoxia in 
the presence or absence of exercise-induced stimuli, 
they observed in the working heart, but not in 
skeletal muscles, a reprogrammed calcium 
signalling which triggered the subsequent increase 
of Mb gene expression independently from HIF-1 
(19).  
 
The doctrine that MB is solely a product of striated 
muscles, lost ground in 2006, when Fraser and 
colleagues demonstrated that the hypoxia-tolerant 
common carp (Cyprinus carpio) has Mb not only in 
muscle but also in other metabolically active tissues 
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including liver, brain, and gills (20). More than 
that, the carp generates not one but two Mbs from 
distinct genes (Mb-1, Mb-2) of which one (Mb-1) 
was robustly induced as transcript and protein in 
all non-muscle tissues upon exposure of the fish to 
day-long O2 deprivation. Both proteins also occur 
in non-muscle tissues of the closely related and 
equally hypoxia tolerant goldfish (Carassius 
auratus) (21). MB is also present in smooth 
muscles of birds [i.e. the gizzard (22)] and humans 
[i.e. rectal sphincter (23)]. In addition, low levels 
of MB are variably detected in different malignant 
tumors of human subjects, including breast cancer 
(24-28), but the physiological function of 
endogenous MB in cancer cells remains a mystery. 
 
We recently conducted the first comprehensive 
analysis of MB expression in a large and 
representative cohort of human breast cancer (29). 
Subsequently, we documented other globins, 
namely hemoglobin and cytoglobin to also be 
expressed in human breast cancer and have begun 
to unravel their functional implications in this 
setting (30). In the current study we focus on the 
mechanistic details of human MB expression in 
malignant breast carcinomas and cancer cell lines. 
Carcinoma-expressed MB was found strongly 
associated with known marker genes of hypoxia. 
Cultured human breast cancer cells, but not healthy 
breast epithelial cells, robustly induce the 
expression of MB mRNA and protein when 
challenged by prolonged hypoxia. This induction 
by hypoxia requires, to a large extent, 
transactivation by HIF-1 and -2. Transcription of 
the MB gene in breast cancer cells is launched via a 
novel, alternative start site 6 kb upstream of the 
translation initiation codon. In line with the gene`s 
hypoxic activation, the alternative start site is 
flanked by a functional hypoxia response element 
(HRE). RNA interference-mediated silencing of 
MB function suggested that the hemoprotein is 
involved in regulating respiratory, proliferative and 
motility activities in oxygenated and hypoxic 
breast cancer cells. Accordingly, MB in breast 
cancer might aid in adjusting the cells` 
proliferative and oxidative capacities during 
prolonged hypoxia. In addition, MB promotes the 
growth of fully oxygenated breast cancer cells, 
perhaps through controlling fatty acid homeostasis 
and lipogenesis (29). 
 
 
 
 
Experimental procedures 
 
Cell lines and hypoxia exposures 
Human mammary epithelial cell line MCF12A and 
the breast cancerous cell lines MDA-MB231, 
MDA-MB468, and MCF7 were obtained from 
ATCC (Rockville, MD, USA) and cultured as 
recommended. Culture atmospheres included: 
normoxia = ventilated room air in water-saturated 
5% CO2 atmosphere = 141.6 mm Hg or 18.6% O2 
(sea level, 37 °C); hypoxia = water-saturated 1% O2 
/ 5% CO2 / balance N2 atmosphere at 37 °C. We 
used Hera cell240 incubators (MultiTemp Scientific 
AG, Kloten, Switzerland), an IG150 incubator 
(Jouan, Unterhaching), a CB 53 CO2 incubator 
(Binder), a polymer Coy glove box (Coy Laboratory 
Products Inc., Grass Lake, MI, USA) or InvivO2 
400 Hypoxia Workstations (Ruskinn Technology 
Ltd, Leeds, UK) for hypoxic exposures. 
 
Quantitative real-time reverse transcription PCR 
qPCR experiments used the ABI Prism 7500 Fast 
SDS (Applied Biosystems, Darmstadt, Germany) 
and primers given in Table 1 (see (31) for details). 
Mean (±SD) expression levels of standard 
(NM_005368, MB-S) and alternative (NM_203377, 
MB-A) MB transcript were calculated by the 
standard-curve approach measuring Ct-values for 
hypoxic and normoxic samples (n=2 experiments, 
triplicate assays). Differences in relative abundance 
between MB-S and MB-A transcripts in normoxic 
MDA-MB468 cells were calculated using the 
standard-curve method and a standard plasmid 
construct harboring both amplicons, MB-S and MB-
A (n=4 experiments, duplicate assays).  
 
Western blots 
Following normoxic exposure for 72 h and hypoxic 
(1% O2) exposure for 4, 8, 24, 48 and 72 h MDA-
MB468 and MCF7 were harvested with a lysis 
buffer containing 0.1% NP-40, 400 mM NaCl, 1 
mM EDTA (pH 8.0), 10 mM Tris-HCl (pH 8.0) and 
protease inhibitors. Protein extracts were 
electrophoresed on a 15% SDS-PAGE gel. Primary 
antibodies (Abs) included: a) monoclonal Ab (mAb) 
mouse anti-myoglobin (Cat. No. 113-0533, clone 
Z001, Zytomed Systems GMBH, Berlin, Germany; 
dilution: 1:1000); b) anti-HIF-1α mouse mAb 
(mgc3; 1:500); c) anti-HIF-2α rabbit polyclonal Ab 
(NB100-480, Novus Biologicals, LLC, Littleton, 
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USA; 1:750). For equal loading control, blots were 
stripped and re-probed by mAb mouse anti-β-Actin 
at a 1:5000 dilution (A5441 Sigma-Aldrich, Basel, 
Switzerland). 
 
Identification of candidate transcription factor 
binding sites 
Genomic sequences covering the analyzed gene 
loci were extracted from the NCBI database 
(www.ncbi.nlm.nih.gov): human MB 
(NC_000022), mouse Mb (NC_000081) and 
human HSP27 (NC_000007). Putative 
transcription factor binding sites conserved across 
different species were identified using the rVISTA 
program (32) (http://rvista.dcode.org) whose 
searches utilize the TRANSFAC database 
(http://transfac.gbf.de/TRANSFAC/) (33). A 
global sequence alignment file as prepared by the 
program Mulan (http://mulan.dcode.org/) was used 
as input.  
 
Functional analysis of the candidate HRE via dual 
luciferase reporter assays 
A genomic region of 376 bp that comprised the 
candidate HRE was amplified from human 
placenta DNA (obtained from the Institute of 
Gynecology, University Hospital Mainz) using 
PCR primers listed in Tab. 1. The fragment was 
directionally cloned in a pGL3 promoter vector 
(Promega). MDA-MB468 cells were transfected 
using the FuGENE-HD reagent (Promega). For 
normalization of transfection efficiencies, all 
samples were co-transfected with a pGL4.74 
vector. To investigate the influence of the 
candidate enhancer on the translation efficiencies 
of the coding DNA sequence (CDS) upon hypoxia, 
dual luciferase reporter assays (DLRA) were 
performed at 72 h post transfection. Light signal 
quantification was measured in a Glomax 96 well 
luminometer (Promega), choosing a sample 
volume of 40 µl on both luciferin reagents (n=4 
experiments, triplicate assays). Standard deviations 
were calculated via Excel 2003 (Microsoft). 
 
Stable and transient RNA interference 
a) Targeting HIF 
The following RNA oligonucleotides were 
synthesized to target a) nucleotides 1380-1400 of 
human HIF-1α mRNA (accession no. AF304431.1) 
as sense 5’-CUGAUGACCAGCAACUUGAdTdT-
3’ and antisense 5`-UCAAGUUGCUGGUCAUC-
AGdTdT-3’ sequences; b) nucleotides 1260-1280 
of human HIF-2α (accession no. NM_001430) as 
sense 5’-CAGCAUCUUUGAUAGCAGUdTdT-3’; 
and antisense 5’-ACUGCUAUCAAA-
GAUGCUGdTdT-3’ sequences. Both siRNAs, and 
the SiCONTROL non-targeting pool #2 of 
scrambled siRNAs, were purchased from 
Dharmacon Research Inc. (Lausanne, Switzerland). 
6-well plate oligofectamine transfections 
(Invitrogen, Basel, Switzerland) of siRNAs used 
final concentrations of 200 nM of either HIF-1α or -
2α single siRNA, and 100 nM each of HIF-1α and -
2α siRNA in combined transfections. 
 
b) Targeting MB 
Short hairpin RNAs (shRNA) were used for 
targeting human MB mRNA (GenBankTM accession 
number NM_203377) at nucleotides 284-304 
(construct #83), 483-503 (#84), 340-360 (#85) and 
415-435 (#86). Inserted into the mammalian 
expression vector pLKO.1-puro, these four shRNA 
constructs were purchased as bacterial glycerol stock 
from Sigma-Aldrich (Basel, Switzerland). Stable 
shRNA MB knockdown MDA-MB468 cells were 
established by overnight calcium phosphate 
transfection followed by selection and maintenance 
in 0.75 µg/ml puromycin containing medium. For 
transient knockdown, MDA-MB468 cells were 
lipofectamine transfected (Invitrogen, Basel, 
Switzerland) with 20 (i.e. for knockdown 0-72h) or 
100 pmole (i.e. for knockdown 0-144h) siRNA (#6, 
#8) or allStars negative control scrambled RNA 
(Qiagen, Hilden, Germany). Knockdown efficiency 
was confirmed on protein and/or RNA level using 
Western Blot and real-time qPCR, respectively, as 
above. 
 
High-resolution respirometry 
Oxygen kinetics of trypsinized, suspended and 
heavily stirred MDA-MB468 cells, both of MB 
control and knockdown make-up, were measured at 
~1x106/ml densities in twin-chamber Oroboros® 
Oxygraph-2k high-resolution respirometers as 
previously summarized (34-36). Each chamber was 
filled with cells suspended in 2 ml culture medium 
(glucose-free DMEM + 10% FBS + 
penicillin/streptomycin + 0.75 μg/ml puromycin). 
To measure routine respiration, the medium was 
initially free of glucose. Later, 25 mM of glucose 
were added to measure the extent of its inhibition on 
respiration. To control oxygen levels and record 
sequentially replicated aerobic-anoxic transitions of 
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respiratory activity of MDA-MB468 cells, 
injections of 40 μM H2O2 triggered the release of 
controlled amounts of oxygen since the medium 
also contained 280 IU/ml of catalase. Catalase 
dismutates rapidly hydrogen peroxide into oxygen 
and water such that the small amounts of added 
hydrogen peroxide do not induce any oxidative 
stress (37). For the recording of maximum oxygen 
flow as a measure of mitochondrial electron 
transfer capacity (ETS), oxidative phosphorylation 
was uncoupled with increasing doses (4.0 - 5.5 
μM) of the protonophore carbonylcyanide-4-
(trifluoromethoxy)-phenylhydrazone (FCCP). 
Finally, mitochondria were poisoned through 
injection of 0.5 μM of myxothiazol to obtain the 
residual O2-consumption (ROX). The oxygen 
partial pressure supporting half-maximal 
respiratory flux, p50(O2), was calculated from 
aerobic-anoxic transitions in the routine state of 
respiration (with and without glucose in the 
medium), fitting a hyperbolic function between 
respiration, R, and oxygen pressure, pO2, using the 
Hill equation, R = Rmax·pO2/(pO2 + p50). 
 
In vitro proliferation, mitochondrial activity and 
migration assays 
Proliferation rates of wildtype (wt) and selected 
stable MB-control (con) or MB-knockdown (kd) 
MDA-MB468 clones was determined over a 96 h 
time course in normoxic and hypoxic atmospheres 
by direct counting of viable cells (Trypan Blue 
exclusion assay). In addition, we used the MTT 
(Dimethylthiazolyldiphenyltetrazolium Bromide) 
assay to infer viability from the colorimetric 
measurement of mitochondrial dehydrogenase 
activity in MDA-MB468 cells transfected with 
MB-silencing siRNA or scrambled (scr) control 
RNA oligonucleotides as a function of four 
different O2 concentrations (normoxic atmosphere, 
5%, 1%, 0.2% O2) over a 144 h time course. 
 
In vitro motility of MDA-MB468 cells was 
assessed in transiently siRNA-transfected cells by 
performing a monolayer scratch wound assay at 
normoxic and hypoxic tensions (38). The wound 
closure dynamics was determined as percentage of 
remaining wound size by evaluation the acellular 
gap width in relation to the initial wound width at 
three different sites for each wound in each picture 
(data as mean relative wound size ± SD of 
triplicate measurements/clone).  
 
 
 
Statistical Analysis 
Expression analysis (mRNA, protein), siRNA 
treatment, MTT assays and respirometry results 
were analyzed using the package STATA 10.0 
(Stata™ 10.0; StataCorp, College Station, USA). 
Mean MB or CaIX mRNA and MB protein 
induction levels along a hypoxia time course (4, 8, 
24, 48, 72 h - 1% O2) were compared with basal 
abundance in normoxia controls (72 h). Also, MB 
induction was compared for corresponding time 
points between siControl versus siHIF-1α or siHIF-
2α or the combined siHIF-1α/-2α treatments. Mean 
O2 consumption rates or p50 measurements were 
compared pairwise between pooled MB control 
(con) and knockdown (kd) samples. Statistical 
significance was calculated by i) unpaired Student t-
tests or one-way ANOVA when normality of data 
population and variance equality among samples 
was ascertained (e.g. MB mRNA induction; MTT 
assay: scr versus si activity at same O2 and time 
point; respirometry: R(-G), R(G), ROX O2 
consumption rates, all p50 data) or ii) Welch-
approximated t-tests allowing unequal variances 
(e.g. MB protein induction; siRNA 72 hours hypoxia 
time point comparison; ETS consumption rate). P 
values < 0.05 were considered significant. 
 
 
Results 
 
We recently described that MB in breast cancer is 
positively and significantly correlated with estrogen 
(ERα), progesterone receptor (PgR), hypoxia-
inducible factor 2a (HIF-2α) and carbonic 
anhydrase IX (29). The typical expression profile of 
a MB-positive case is shown in Fig. 1: strong 
expression of MB and ERα, moderate but clearly 
discernible HIF-2α and CAIX expression, and weak 
expression or absence of HIF-1α and GLUT1. The 
positive correlation of MB with markers of tissue 
hypoxia (CaIX and HIF-2α) implied a possible 
control of MB expression by O2. To clarify if MB 
expression also correlates with hypoxic tissue areas 
in vivo, we reanalysed 137 cases of ductal 
carcinoma in situ (DCIS). DCIS represents an 
interesting in vivo model for hypoxia research since 
this tumor has no intraductal vasculature. Thus, 
ambient oxygen can only be supplied by diffusion 
across the outer basal membrane. This forms a 
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radial O2 diffusion gradient (normoxic rim; 
hypoxic to anoxic centre) along with a central 
necrotic area (Fig. 2). Expression of the hypoxia-
driven GLUT1 protein closely followed this 
gradient in our cohort of DCIS and showed a 
typical zonal distribution in 65% of cases (Fig. 
2A). However, with regard to MB only in 27% of 
MB-positive DCIS cases a hypoxia-like gradient 
with stronger staining in the peri-necrotic region 
was found (Fig. 2A). The majority of cases (73%) 
showed a diffuse MB immunoreactivity (Fig. 2B). 
This indicates that hypoxia may up-regulate MB in 
vivo, although in the majority of cases stimuli other 
than low pO2 are driving the induction of MB. A 
similar conclusion was reached when we assessed 
the possible co-localization between MB and 
hypoxic tumor areas as indicated by the hypoxia 
marker pimonidazole (Fig. S1). 
 
We subsequently analyzed the responsiveness of 
the MB gene towards hypoxia (1% O2) by 
quantitative real-time PCR (qPCR) in the benign 
breast cell line MCF12A and three breast cancer 
cell lines (MDA-MB231, MDA-MB468, MCF7). 
Whereas hypoxia did not affect the transcription of 
MB in benign MCF12A cells (Fig. S2), normalized 
steady state levels of MB mRNA increased 3-4 fold 
in hypoxic MDA-MB231 (not shown), MDA-
MB468 and MCF7 cells (Fig. 3A). For all cases, a 
significant activation of the MB gene required at 
least 24 h or 48 h of hypoxia treatment. Proper 
hypoxic responsiveness of MCF7 cells was 
confirmed through assessment of transcription of 
the highly hypoxia-inducible CaIX transcript (Fig. 
3A). 
 
Of all examined breast cancer cell lines MDA-
MB468 cells contained the most abundant levels of 
MB transcripts under basal conditions (29). 
Superior abundance of MB in MDA-MB468 cells 
was also seen at protein level (i.e. MDA-MB468: 
65 ng protein/106 cells (29); other breast cancer 
cell lines contain 24-32 ng MB/106 cells (28)). 
Exceeding hypoxia (1% O2) over 48 h (Fig. 3B) in 
MDA-MB-468 (left panel) and MCF7 cells (right 
panel) induced MB protein expression between 
3.4- and 5.1-fold. The hypoxic response was 
transient when centered around HIF-1α (MCF7) or 
persistent (up to 72 h, 1% O2) when HIF-2α acted 
as the predominant regulator (MDA-MB468) (Fig. 
3B). 
 
Next, HIF`s role in the hypoxic induction of MB 
was examined using HIF-1α and HIF-2α  siRNA 
oligonucleotides. The siRNA assay focused on 
scrambled control and HIF-1α (= siHIF-1α), -2α (= 
siHIF-2α) and combined knockdown (kd) effects (= 
siHIF-1α/2α) after 52 h to 96 h of exposure to 1% 
O2 (Fig. 3C). Levels of MB steadily increased 
during siControl transfections to reach a maximal 
~7-fold induction at 72 h hypoxia (Fig. 3C). This 
peak induction was partially reduced upon HIF-1α 
or -2α single siRNA treatment. Yet, the combination 
of both siRNAs yielded a ~20% residual amount of 
either HIF factor which significantly attenuated the 
MB induction to ~1.7 fold at 72 h hypoxia. In 
conclusion, this finding implies that both HIF-1 and 
HIF-2 participate in transactivating the MB gene by 
hypoxia. 
 
To follow-up on this hypoxic transactivation of the 
MB gene by HIF-1/-2, we compared the human MB 
gene locus to expressed sequence tags (EST) and 
detected the presence of several alternatively 
spliced MB transcripts in addition to the published 
mRNA (39). These transcript variants contain 
different non-coding 5’- untranslated regions (5´-
UTRs), hence are transcribed from different MB 
promoters (Fig. 4A). Comparison of EST numbers 
revealed that mRNA NM_005368 (NCBI-AceView 
Hsa MB variant B (40)) is the dominant ‘standard’ 
transcript (MB-S) in muscle tissues of skeletal and 
heart. Transcript NM_203377 (NCBI-AceView Hsa 
MB variant D) was found encoded by the majority 
of cancer-associated EST reads. This mRNA 
(designated “MB-A” for “alternative”) thus 
represented a candidate for analyzing its expression 
in breast cancer cells (Fig. 4A). Calculating the ratio 
of MB-S versus MB-A mRNA expression levels in 
normoxic MDA-MB468 breast cancer cells revealed 
a clear preference for MB-A, which was roughly 300 
fold more abundantly expressed than MB-S (Fig. 
4B). In MDA-MB468 cells subjected to either 
normoxia or 1% O2 for 72 h, the steady-state levels 
of MB-S were unaltered. On the contrary, the 
amount of MB-A transcripts increased 2.2 fold in 
hypoxic compared to normoxic cells. Using the 
rVISTA tool we inspected the genomic regions of 
human and mouse MB/Mb genes for the presence of 
HIF binding hypoxia response elements (HREs), as 
characterized by the conserved consensus motif 5´-
RCGTG-3´  
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(41). We detected one putative HRE at ~2.7 kb 
upstream of exon 1 (Fig. 4A), which consists of 
two inverted HIF-1 binding sites at an interval of 6 
bp contained within a conserved stretch of 53 bp. 
This candidate MB-HRE has 92% sequence 
similarity to an upstream promoter region from the 
human heat shock protein HSPB1 gene (Fig. 4C). 
 
To investigate the functionality of the candidate 
HRE, dual luciferase reporter assays (DLRA) were 
performed. MDA-MB468 cells were transfected 
with pGL3 promoter constructs that comprised a 
376 bp section around the candidate HRE. 72 h 
post transfection, normalized luciferase activity 
was quantified in cell batches raised either under 
normoxic or hypoxic conditions (Fig. 4D). During 
hypoxia, the HRE encoding construct showed an 
enhancer activity, which increased the amount of 
generated transcript by 43%, compared to the 
pGL3 promoter vector as a control. Under 
normoxia no enhancer activity of the construct was 
observed. 
 
To unravel functional properties of endogenous 
MB in breast cancer cells, we generated stable MB 
knockdown clones of MDA-MB468 cells using 
four different short hairpin (sh) RNA constructs 
(#83-86). Applying Fick’s law of diffusion, we 
aimed to see if the shRNA-mediated loss-of-
function (LoF) of MB would yield a steeper 
oxygen diffusion gradient reflected by a higher 
p50(O2) of cell respiration at identical oxygen flow. 
O2 consumption kinetics were investigated by 
high-resolution respirometry using two control 
(con) clones (boxed: 84#5 and 85#14) and two 
knockdown (kd) clones (boxed: 83#4, 84#31) (Fig. 
5A). O2 flow per second and million cells (red 
tracing) was recorded as a function of O2 
concentration (blue tracing) across four cellular 
activity states (Fig. 5B): i) routine respiration 
without glucose [= R(-G)]; ii) routine respiration 
with 25 mM glucose [= R(G)]; iii) maximal 
respiration through uncoupling of oxidative 
phosphorylation by FCCP [= ETS]; iv) residual O2 
consumption after poisoning of mitochondria with 
myxothiazol [=ROX]. R(-G) and R(G) states 
indicate oxygen consumption at higher versus 
lower fluxes, respectively (Crabtree effect). To our 
surprise, all mitochondrial and residual O2 fluxes 
were significantly increased in MB kd cells 
compared to control cells (Fig. 5C). In contrast, 
mean cellular cytochrome c oxidase p50(O2) 
values (i.e. p50(O2) of respiration) under R(-G) and 
R(G) conditions were statistically indistinguishable 
in control versus kd cell comparisons for either 
glucose-deficient or -proficient respiration (Fig. 
5D). Differences in p50 values from high versus low 
oxygen fluxes were also non-significant.  
 
We also investigated cellular proliferation during a 
0-48-96 h time course in wildtype (wt) and stable 
MB-control (con) and MB-knockdown (kd) MDA 
transfectants under both normoxic (continuous 
lines) and hypoxic (1% O2, hatched lines) 
atmospheres by employing Trypan Blue-exclusion 
assays (Fig. 6A). MB LoF in stable knockdown 
transfectants yielded a significant diminishment of 
viable cells over the 96 h course, relative to wt cells 
or control transfectants, in both normoxic and 
hypoxic conditions. 
 
Next, we assessed MDA-MB468 viabilities at 
normoxic and hypoxic pO2 following siRNA-based 
transient silencing of MB expression to generate 
LoF phenotypes. This time we employed MTT 
assays during which mitochondrial dehydrogenases 
reduce a yellow tetrazolium substrate into a purple 
formazan compound as proxy for the oxidative 
capacity of living cells. Prior to the assay, cells were 
transfected with scrambled (scr) or MB-silencing 
siRNA (si) oligonucleotides. MTT reduction was 
followed over a 0-48-96-144 h time course as a 
function of four different O2 concentrations: 
normoxia and 5%, 1% or 0.2% O2. Control RT-PCR 
analyses of MB mRNA expression assured the Mb 
knockdown effect to last over the entire 144 h course 
(Fig. 6B: gel picture under graph). As expected, 
MTT conversion increased, due to continued cell 
and mitochondrial proliferation, linearly and with 
equivalent slopes over time in oxygenated cells (Nx, 
5% O2), suggesting respiration of MDA-MB468 
cells to operate in an oxyregulated fashion between 
20-5% O2. Compared to that, MTT conversion rose 
far less at 1% O2 or was even ~2-fold inhibited 
during the time course at 0.2% O2. Of note, pairwise 
comparisons of scr (continuous lines with filled 
symbols) versus MB-silencing treatments (hatched 
lines with hollow symbols) were, at the same O2 
conditions and time points, statistically 
indistinguishable in high oxygen (Nx, 5% O2) while 
revealing a borderline significant benefit of the MB 
knockdown on the activity of the MTT-converting 
mitochondrial enzymes in hypoxic cells (see scr/si p 
values at 0.2% O2 course; Fig. 6B). 144 h si/scr 
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ratios of MTT reduction rose steadily from near-
equality at 5% O2 to a +18% (1% O2) and, 
eventually, +46% (0.2% O2) benefit in MB-
silenced cells facing hypoxia (Fig. 6B). 
 
Finally, we considered whether MB expression in 
breast cancer cells also influences the migration of 
normoxic or hypoxic cells on basis of a scratch 
assay. As can be seen in Figs. 6C and 6D, control 
cells (i.e. wild type MDA cells, either untreated or 
treated with scrambled RNA) were able to 
reconstitute the gap notably faster than MB kd 
cells treated with siRNA #6 or #8. This remarkable 
retardation of the in vitro motility in cells with 
repressed Mb expression established, especially 
after prolonged (48 h + 72 h) cultivation, a good 
agreement between loss of MB and impaired 
cellular migration potential in high and low pO2. 
 
 
Discussion 
 
To date, the existence of regional hypoxia in most 
solid tumors (for review: (42-45)), including breast 
cancer (46), has been clearly established. Tumor 
hypoxia often associates with therapy resistance 
and poor prognosis. In accordance with Flonta et 
al. (28), we demonstrate de novo expression and 
hypoxic responsiveness of human MB mRNA and 
protein in human breast cancer cell lines. In 
contrast to non-transformed epithelial cells, 
malignant breast cancer cells induced both MB 
mRNA and protein 3-7 fold in response to 
prolonged exposure to 1% O2. Peak induction of 
the MB protein in chronically hypoxic MDA-
MB468 cells further required the involvement of 
HIF-1 and HIF-2 protein. We further noted that the 
standard TATA box promoter of both human and 
mouse MB/Mb genes (39,47), which drives the 
expression in striated muscle cells, lacks candidate 
HREs (17). Consequently, we found expression of 
the standard MB transcript (NM_005368; MB-S) to 
not be affected by O2. However, a non-canonical 
MB mRNA (NM_203377; MB-A), transcribed 
from a novel promoter proximal to the 5’ UTR 
upstream exon, greatly exceeded in MDA-MB468 
cells the copy numbers of the MB-S mRNA, 
suggesting that MB-A, tentatively, can be regarded 
as a cancer-specific transcript. Discovery of the 
O2-responsiveness of MB-A, in conjunction with 
the found HIF-1/-2-driven transactivation of the 
MB gene during hypoxia, was backed by the 
presence of a candidate HRE at ~2.7 kb upstream of 
exon 1 of the MB gene. The motif consists of two 
inverted HIF-1 binding sites at an interval of 6 bp, 
embedded in a conserved stretch of 53 bp. This 
MB-HRE has 92% sequence similarity to an 
upstream promoter region from the Hsp27 encoding 
human heat shock protein gene HSPB1, which was 
reported to house a functional and HIF-1 binding 
HRE (48). Our preliminary analysis indicates that 
this MB-HRE features an enhancer activity of 43% 
upon exposure to hypoxia. 
 
Based on these findings, we assume that breast 
cancer cells induce MB in response to longer 
periods of low oxygen via an alternative, and 
perhaps, tumor specific promoter whose enhanced 
activity might be also dependent on the binding of 
HIF-1/-2 to the HRE located 2.7 kb upstream of the 
genuine ATG. The statistically significant positive 
correlation of MB with HIF-2α and CAIX in breast 
carcinomas further points towards mechanistic 
networking of these factors under hypoxia. 
However, our in vivo data also provide evidence 
that MB can be expressed by breast epithelia 
irrespective of hypoxia (29) and that even severe 
hypoxia in pimonidazole-stained carcinoma does 
not necessarily trigger MB induction (Fig. S1). 
 
MB has multiple known or alleged functions in 
muscle tissue including short-term O2 storage and 
buffering, facilitating O2 diffusion, scavenging of 
NO and ROS and also the reverse (peroxidase 
activity, NO production) and the binding plus 
transport of fatty acids (2-4,6-11,49). To assess 
whether MB also confers O2-buffering or facilitates 
O2 diffusion in cancer cells we used high-resolution 
respirometry to measure O2 consumption kinetics in 
MB expressing (con) and knockdown (kd) MDA-
MB468 cells, expecting the latter to develop higher 
intracellular oxygen gradients (reflected by a higher 
p50(O2) of cell respiration at identical oxygen flow) 
than controls. Because facilitated diffusion of 
oxygen can only occur when MB is partially 
desaturated with oxygen, the above prediction of 
Fick`s law of diffusion was carefully assessed with 
pO2 ≤ 1.1 - 0 kPa (= 8.3 - 0 mmHg; see blue tracing 
of [O2] in Fig. 5B and note development of 
controlled amounts of oxygen by H2O2 injections 
into catalase-containing medium to generate 
replicate aerobic-anoxic transitions and, thus, a 
more accurate determination of p50(O2) of cell 
respiration (37)). With the 37°C-half saturation (Y50) 
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of MB occurring at pO2 of 2.4 mmHg (50), a 
transition from 1.1 to 0 kPa corresponds to a 
fractional O2 saturation of MB ranging from ~78% 
to complete deoxygenation (see Experimental 
Procedures for details). While our respirometric 
conditions were well suited to trigger MB into O2 
unloading and to potentially detect any facilitated 
O2 diffusion, it needs to be stressed that p50(O2) 
measures of respiration of small cells and isolated 
mitochondria usually are below 0.1 kPa (51). Thus, 
only a small scope for intracellular oxygen 
gradients exists (51). Within these physical 
constraints the present study was unable to provide 
any evidence for O2 gradients that are differentially 
influenced by the presence or absence of MB 
protein. In fact, the p50(O2) of MB con and kd 
MDA-MB468 cells was found to lie in a similar 
range (0.08 kPa). These results do not suggest a 
functional role of MB in oxygen transport in small, 
suspended cells in vitro. However, they do not 
exclude the possibility of larger oxygen gradients 
developing in the solid tumor and a potential 
contribution of MB to facilitated oxygen diffusion 
under in vivo conditions. Furthermore, routine 
respiration in MDA-MB468 cells was activated 
~55% [i.e. R(-G)] and ~40% [i.e. R(G)], 
respectively, of the mitochondrial capacity for 
electron transfer (ETS), which is comparable to 
various primary cultured cells such as HUVEC and 
fibroblasts (34,52,53). Mitochondrial oxygen 
kinetics and coupling control in malignant MDA-
MB468 cells, therefore, is not indicative of a 
mitochondrial deficiency frequently considered as 
a specific feature (Warburg effect) of cancer cells. 
 
In addition to these respirometry data from O2-
limiting hypoxia, we also noticed the intensified O2 
uptake rate across all four physiological activity 
states considered [R(-G), R(G), ETS, ROX] by 
MDA knockdown cells during mild hypoxia. As a 
hemoprotein, MB can effectively interact with the 
gaseous nitric oxide (NO). MB knockout mouse 
models (1,5) have been instrumental to elicit MB`s 
critical role in maintaining NO homeostasis in 
muscle tissue. Whether MB expressed in 
neoplasms exerts similar controls remains to be 
seen. At this point we can only speculate that the 
respiratory activation and enhancement of 
substrate turnover by MTT-converting 
mitochondrial dehydrogenases, both noted for 
hypoxic MDA cells in response to MB LoF, might 
result from the capacity of the oxygenated fraction 
of MB (i.e. MBO2) to scavenge NO (i.e. NO + 
MBO2 " metMB + NO3-), a key stimulus of 
mitochondrial biogenesis (54). Alternatively, 
presence of MB may also exert some oxidative 
stress (i.e. bound O2 is released as reactive oxygen 
species) particularly during stages of hypoxia, and 
in that way act to inhibit mitochondrial activity. Our 
results on oxygen kinetics, however, suggest that 
MB does not play a detectable role in regulating 
OXPHOS-inhibiting levels of NO in suspended 
breast cancer cells. Using iNOS transfected HEK 
293 cells to achieve regulated intracellular NO 
production, on the other hand, demonstrated that 
nM concentrations of NO could trigger an increase 
of low p50(O2) (i.e. <0.1 kPa) values by two orders 
of magnitude, which underpinned the tight coupling 
between NO homeostasis and O2 consumption 
kinetics in this cell model (55). 
 
So far only two studies have analysed the potential 
roles of myoglobin in non-muscle contexts by 
employing artificial expression systems. Nitta et al. 
induced MB expression in hepatocytes by an 
adenoviral gene transfer, which were henceforth 
significantly more resistant to hypoxia (56). 
Galluzzo et al. were the first to introduce abundant 
levels of mouse Mb into the human tumor cell line 
A549 (lung carcinoma) by lentiviral gene transfer 
(57). Experimental tumors expressing ectopic Mb 
displayed reduced or no hypoxia, minimal HIF-1α 
levels, lower vessel density along with a more 
differentiated cancer cell phenotype and largely 
suppressed local and distal metastatic spreading. 
The authors correlate these beneficial outcomes of 
Mb over-expression primarily with the reduction of 
tumor hypoxia (57). Although these findings appear 
to match our in vivo observation from patients, 
where patients with higher MB levels show a better 
prognosis (29), both situations are quite different. 
First, the low quantities of endogenous MB 
measured by us in normoxic MDA-MB468 breast 
cancer cells (~65 ng MB protein/106 cells) cannot 
confer meaningful O2 storage/buffering capacity. 
Secondly, our respirometry data failed to provide 
evidence for a functional role of MB in the transport 
of oxygen in vitro. Lastly, at least in hypoxic breast 
cancer cells, MB has an interfering (i.e. not 
promoting) impact on O2 uptake and oxidative 
energy metabolism, which suggests a tumor-
suppressive function of MB in deoxygenated 
malignancies. These fundamental discrepancies 
require, in our opinion, a cautionary note when 
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overexpression-based molecular evidence is 
directly interpreted in terms of endogenous protein 
functions.  
 
In summary, MB abundance in breast cancer cells 
is regulated not only by estrogen signalling and 
possibly fatty acid levels or growth factors, but 
also by hypoxia (29). The intensified respiration 
and mitochondrial enzyme activities in hypoxic 
cancer cells in response to a silencing of MB 
expression might either result from mitochondrial 
compensation(s) (e.g. increase in mitochondrial 
density/size due to NO overabundance) or, perhaps, 
reflect a higher level of oxidative stress exerted by 
the presence of this hemoprotein. The fact that MB 
LoF yields declining proliferation or motility rates 
even in fully oxygenated cells suggests MB in 
cancer cells to occupy rather unconventional 
functions that are not directly related to the binding 
and transport of O2. By acting as a putative shuttle 
for fatty acids, MB could possibly support active 
lipogenesis and cellular growth even at times when 
the O2 supply is non-limiting and the protein is in 
its fully O2-saturated state (i.e. MBO2). Beyond 
these functional aspects, the regulation in normal 
and tumor tissue might also be fundamentally 
different, as the novel description of a tumor 
specific MB transcript suggests. Together, these 
findings further broaden our view on the role of 
non-muscle MB that may have fundamental 
implications for our conception of the biology of 
solid tumors. 
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Table 1 Primers used for real time PCR and the generation of a HRE luciferase reporter construct 
(MluI and XhoI restriction enzyme recognition sites are underlined) 
 
Gene Primer sequence Product size 
Myoglobin 
5´- GGCATCATGAGGCAGAGATT – 3´ 
111 bp 
5´- TCTGCAGAACCTGGATGATG – 3` 
 
 
 
MB-CDS 
5´- GAGATGAAGGCGTCTGAGGA – 3´ 
294 bp 
5´- AACTACAAGGAGCTGGGCTTC – 3´ 
 
 
 
GAPDH 
5’-GAAGGTGAAGGTCGGAGTCA-3’ 
289 bp 
5’-TGGACTCCACGACGTACTCA-3’ 
   
ß-Actin 
5’- GGACGACATGGAGAAAATC-3’ 
185 bp 
5’- ATAGCACAGCCTGGATAGC-3’ 
   
MB-s 
(NM_005368) 
5´- CCCAGTGAGCCCATACTTGC -3´ 
219 bp 
5´- GTCAGAGGACGAGATGAAGGC -3´ 
   
MB-a 
(NM_203377) 
5´- GCATGTTGGCCTGGTCCTTTGC -3´ 
275 bp 
5´- GTCCTCATCAGGCTCTTTAAG -3´ 
   
L28 NM_000991 
5´-GCAATTCCTTCCGCTACAAC-3´ 
198 bp 
5´- TGTTCTTGCGGATCATGTGT -3´ 
   
HRE construct 
5´- NNNNACGCGTTGGCATCCCCATGGCTTCT -3´ 
376 bp 
5´- NNNNCTCGAGACCTCCAAAGGCCCATCTC -3´ 
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Legends 
 
Fig 1. Immunohistochemistry of MB, ERa and endogenous markers of hypoxia in a typical case 
of moderately differentiated invasive ductal breast cancer. A) Cytoplasmic MB expression is 
abundant. B) Lack of staining for HIF-1α. C) Moderately positive staining (nuclear) for HIF-2α. D) 
Lack of staining for GLUT1 (note erythrocytes staining in the center as internal positive control). E) 
Moderately positive staining for CAIX. F) Strong expression of estrogen receptor (ER)α. 
 
Fig. 2. Ductal Carcinoma In Situ (DCIS) as an in vivo model for tissue hypoxia. The upper panel 
depicts DCIS schematically with a black outer rim (basal membrane), an inner zone (light blue) of 
atypical epithelial proliferates and a central necrosis (black star). Expression of the hypoxia marker 
GLUT1 follows a zonal hypoxic gradient in 65% of DCIS cases (A, middle). However, also diffuse 
GLUT1 staining can be observed (B, middle). MB expression mostly displayed this diffuse staining 
(B, bottom) and showed the typical hypoxia-related zonal pattern in only 27% of cases (A, bottom). 
 
Fig. 3. MB expression in hypoxic breast cancer cells. A) MB (left) and CaIX (right) mRNA 
expression during indicated times of hypoxia (1% O2) in MCF7 cells (normalized expression: MB/L28, 
CAIX/L28; mean ± SD, n=3). Maximal mRNA abundance at 72 h hypoxia was set to 1. Hypoxic 
MB/L28 or CaIX/L28 mRNA expressions (black bars) showing significantly elevated values (p < 0.05, 
<0.01, <0.001) relative to a basal steady state at 72 h normoxia (white bar) are indicated by 1, 2, or 3 
asterisks, respectively. B) Protein expression of (top-to-bottom) HIF-1α, HIF-2α, MB and β-Actin in 
MDA-MB468 (left) and MCF7 (right) cells during indicated times of normoxia and hypoxia (1% O2), 
respectively. Lower bar graphs show the densitometrical summary of mean fold-inductions (± SD, 
n=3) for normalized MB protein expression (i.e. MB/β-Actin) during the hypoxia time course relative 
to the proteins normoxic levels (=1) for MDA-MB468 (left) and MCF7 (right) cells. Hypoxic 
inductions (black bars) showing significantly elevated values (p < 0.05) relative to basal MB levels at 
72 h normoxia (white bars) are indicated by single asterisks. C) Transfection of MDA-MB468 cells 
with scrambled RNA (siControl) or HIF-1α and HIF-2α transcript-targeting siRNAs. Representative 
Western blots show (top-to-bottom) HIF-1α, HIF-2α, MB and β-Actin protein abundance for 96 h 
normoxia versus 52, 56, 72 and 96 h of hypoxia (1% O2). The protein loading control is shown in the 
middle part. Bottom graph: The corresponding MB protein fold-inductions (mean±SD; n=3) during 
indicated hypoxia times are plotted relative to 96 h normoxia (set to 1). Relative to the siControl value 
at a given time point, siHIF-1α, siHIF-2α and siHIF-1α/2α values of MB content were non-
significantly (ns) or significantly different (*, p < 0.05). 
 
Fig. 4: Hypoxia induction of alternative MB transcripts. A) Schematic overview of the Hsa MB 
gene structure, the MB standard transcript NM_005368 (MB-S) and an alternative transcript variant 
NM_203377 (MB-A). Protein encoding exons are indicated by black boxes, untranslated exonic 
regions are hatched. Positions of PCR primers that specifically amplify MB mRNA isoforms are 
indicated by arrows. PCR primers for measuring total MB mRNA levels matched the MB coding 
sequence (CDS primers, filled arrowheads). Open box: a candidate hypoxia responsive element 
(HRE), which consists of two HIF-1 binding sites in inverted orientation (triangles). B) Left: mRNA 
quantification of the MB-S transcript compared to the MB-A transcript variant in MDA-MB-468 cells 
cultured under normoxic conditions (**, p < 0.01; n=4). Middle, Right: Differential expression of the 
transcripts MB-S and MB-A in hypoxic versus normoxic MDA-MB-468 cells (**, p < 0.01; n=4). C) 
Sequence of the candidate MB HRE. Alignment of a 53 bp region (see open box in Fig. 4A) conserved 
between the Hsa MB gene and the HspB1 gene. Two potential HIF-1 binding sites of inverted 
orientation (arrows) are printed in bold. D) Luciferase reporter assays show that the candidate HRE 
features enhancer activity in hypoxic MDA-MB468 cells, compared to normoxic samples. Box plots 
present the range of minimal-maximal samples (lower/upper whisker), the 25% (Q1) to 75% (Q3) 
quartiles (box) and the median (line in box) (**, p < 0.01; n=4). 
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Fig. 5. High-resolution respirometry of control and MB knockdown MDA-MB468 cells. A) MB 
and β-Actin Western blot of 12 MDA-MB-468 shRNA clones, derived from shRNA constructs 83, 84, 
85, together with positive (pos.) MB control extractions from a human skeletal muscle biopsy. MB 
control (84#5, 85#14) and knockdown (83#4, 84#31) clones used for respirometry are boxed. B) 
Original MDA-MB-468 cell respirometry shown as O2 flow per second and million cells (red tracing) 
as a function of O2 concentration (blue tracing) across four cellular activity states: Routine respiration 
without/with glucose [R(-G), R(G)]; maximal respiration through uncoupling of oxidative 
phosphorylation by FCCP [= ETS]; residual O2 consumption after poisoning of mitochondria with 
myxothiazol [=ROX] (see Experimental Procedures for more details). C) O2 consumption rates of MB 
control (con; black + dark gray column) and MB knockdown clones (kd; light gray + white column) 
for the R(-G), R(G), ETS and ROX states. D) Oxygen kinetic p50(O2) data of respiration in MB con 
(black + dark gray column) and MB kd clones (light gray + white column) for R(-G) and R(G) states. 
Mean p50(O2) values are highlighted within the respective column.  
 
Fig. 6. Functional analysis of MB knockdown effects. A) Proliferation assay by Trypan Blue 
exclusion: counts of viable cells were computed over a 0-48-96 h time course of wildtype (WT, 
diamond symbols) MDA-MB-468 cells and stable MB-control (CON, triangles) and MB-knockdown 
(KD, squares) clones under normoxic (continuous lines) and hypoxic (1% O2, hatched lines) 
conditions. Data (mean±SD, n=3) are given in %, relative to 0 h = 100%. B) MTT viability assay: 
Following transfection with scrambled control (scr) or MB-silencing siRNA oligonucleotides (si), 
MDA-MB468 cells were subjected to a 0-48-96-144 h time course at four different O2 concentrations 
(normoxia; 5% O2; 1% O2; 0.2% O2). Given are mean (± SEM, n=4) MTT conversion activities in fold 
changes relative to the 0 h time point (=1). Note the correlation between atmospheric O2 content and 
progressive delay of benefit from the MB knockdown (i.e. shifting of si-MTT > scr-MTT activity cross 
over points for 0.2% " 1% " 5%, Nx to later time points). Gel picture beneath graph: representative 
control RT-PCR of MB and ribosomal protein L28 (loading control) mRNA expression at normoxic 
(N) and 1% O2 hypoxic (H) exposures for indicated time points, in presence of scrambled (scr) or MB 
silencing (si) oligonucleotides. Note the MB knockdown effect to last over the entire 144 h course and 
MB mRNA induction at 1% O2 at 48, 96 and 144 h time points (scr treatment). C/D) Scratch assay for 
investigating cell motility. Confluent MDA-MB-468 cells were scratched with a pipette tip and the 
size of the gap was evaluated after 24, 48 and 72 hours at normoxia (Nx, panel C) or 72 hours at 
hypoxia (Hx, panel D). Diagrams of wound closure over time indicate cell migration capacity. Results 
are averages of triplicate experiments for each approach.  
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Figure S1  Comparison of Mb with the exogenous hypoxia marker Pimonidazole
P
i
m
o
n
i
d
a
z
o
l
e
M
b
A B C
Figure S2  Lack of hypoxic induction of Mb in the normal breast cell line MCF12A
